F12
Coagulation factor XII
As of the edition of 20 October 2026, F12 (coagulation factor XII, UniProt P00748) has 2 drugs tested at it and 1 company on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P00748
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 17
- Disease areas
- Heart and blood vessels; Immune system; Skin and connective tissue; Inherited and neonatal; Nervous system; Lungs and airways; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 20
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Human c1-esterase inhibitor | Marketed | Phase 4 | Ended 2025 |
| Bismuth subgallate | Marketed | No phase stated | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 1 |
| Total on the list | 1 |